Skip to main content
Clinical Trials/NCT02392481
NCT02392481
Completed
N/A

An Exploratory, Prospective, Non-interventional Study Comparing Biomarker Signatures Between Patients With Asthma and Healthy Volunteers and to Investigate Biomarkers Associated With Known Phenotypes Across Asthma Severities

Boehringer Ingelheim4 sites in 1 country69 target enrollmentJuly 16, 2015
ConditionsAsthma

Overview

Phase
N/A
Intervention
Not specified
Conditions
Asthma
Sponsor
Boehringer Ingelheim
Enrollment
69
Locations
4
Primary Endpoint
Level of Tumour Necrosis Factor-alpha (TNF-α) in Blood at Baseline (Visit 1)
Status
Completed
Last Updated
7 years ago

Overview

Brief Summary

The main objective of the trial is to explore if any of the biomarkers assessed are sensitively linked to the asthma phenotypes. This would potentially alone or in addition to other clinical or biofluid markers indicate if and how asthma endotypes are linked to phenotype such as eosinophilic, neutrophilic, or paucigranulocytic phenotypes. Further exploratory markers will be analysed for better understanding of physiological levels of proteins and markers playing a role in regard to disease characterization in asthma. As a basis for further development of a biomarker for asthma, The sponsor plans to conduct this exploratory biomarker trial to determine levels and reference ranges of biomarkers potentially associated with asthma phenotypes. The trial aims at generating a panel of serum biomarkers that can be evaluated in subsequent interventional studies. The longitudinal design will be used to ascertain stability and test-retest reliability.

Detailed Description

Purpose:

Registry
clinicaltrials.gov
Start Date
July 16, 2015
End Date
January 3, 2017
Last Updated
7 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Level of Tumour Necrosis Factor-alpha (TNF-α) in Blood at Baseline (Visit 1)

Time Frame: Baseline (Visit 1)

Level of Tumour Necrosis Factor-alpha (TNF-α) \[picograms per milliliter (pg/mL)\] in blood at baseline (Visit 1) is presented.

Level of Interleukin-6 (IL-6) in Blood at Baseline (Visit 1)

Time Frame: Baseline (Visit 1)

Level of Interleukin-6 (IL-6) (pg/mL) in blood at baseline (Visit 1) is presented.

Secondary Outcomes

  • Level of Tumour Necrosis Factor-alpha (TNF-α) in Blood at Follow-up Visit 28 Days After Baseline (Visit 2)(follow-up visit 28 days after baseline (Visit 2))
  • Level of Interleukin-6 (IL-6) in Blood at Follow-up Visit 28 Days After Baseline (Visit 2)(follow-up visit 28 days after baseline (Visit 2))

Study Sites (4)

Loading locations...

Similar Trials